You say Trintellix, I say Brintellix: Why a drug name in the US won’t always translate across the pondnews2022-01-21T12:07:49+00:00January 21st, 2022|Fierce Pharma|
Fierce Pharma Asia—Lilly-Abbisko cardiometabolic pact; Daiichi Sankyo asset sale; Eisai’s next Alzheimer’s prospectnews2022-01-21T11:45:56+00:00January 21st, 2022|Fierce Pharma|
Ogilvy Health’s new creative chief Hessel reflects on pharma’s pandemic opportunitiesnews2022-01-21T03:25:18+00:00January 21st, 2022|Fierce Pharma|
Blueprint promotes two more execs to C-suite as it looks to realize Ayvakit’s potentialnews2022-01-20T16:12:39+00:00January 20th, 2022|Fierce Pharma|
Fierce JPM Week: AstraZeneca cancer R&D head marks Imfinzi as ‘core backbone’ of oncology strategy with the right combo—including tremenews2022-01-20T15:00:26+00:00January 20th, 2022|Fierce Pharma|
Goodbye Humira, hello Dupixent: Sanofi and Regeneron outspend AbbVie to top 2021’s pharma TV ad spendersnews2022-01-20T14:48:07+00:00January 20th, 2022|Fierce Pharma|
Viatris yanks one batch of diabetes med Semglee because of missing label risksnews2022-01-20T14:41:53+00:00January 20th, 2022|Fierce Pharma|
Merck scores a win in $1.4B insurance fight over devastating cyberattacknews2022-01-20T14:30:33+00:00January 20th, 2022|Fierce Pharma|
NantWorks founder Soon-Shiong plans vaccine plant in South Africa, pledges $6.5M to train workersnews2022-01-20T14:27:32+00:00January 20th, 2022|Fierce Pharma|
Merck’s Clyburn headed for the exit, opening top human health spot at the New Jersey pharma giantnews2022-01-20T13:47:24+00:00January 20th, 2022|Fierce Pharma|
